EP2920305A1 - Neue zellspezifisch wirksame nukleotid-moleküle und applikationskit zu deren anwendung - Google Patents
Neue zellspezifisch wirksame nukleotid-moleküle und applikationskit zu deren anwendungInfo
- Publication number
- EP2920305A1 EP2920305A1 EP13814439.9A EP13814439A EP2920305A1 EP 2920305 A1 EP2920305 A1 EP 2920305A1 EP 13814439 A EP13814439 A EP 13814439A EP 2920305 A1 EP2920305 A1 EP 2920305A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- nucleotide
- nucleotide molecules
- molecules
- bound
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002773 nucleotide Substances 0.000 title claims abstract description 74
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 73
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 39
- 229920000642 polymer Polymers 0.000 claims abstract description 19
- 108020004999 messenger RNA Proteins 0.000 claims description 40
- 239000003708 ampul Substances 0.000 claims description 14
- 239000004055 small Interfering RNA Substances 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 230000004071 biological effect Effects 0.000 claims description 12
- 102000035195 Peptidases Human genes 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 230000002779 inactivation Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 5
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 239000002679 microRNA Substances 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 229920002873 Polyethylenimine Polymers 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000013024 dilution buffer Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000011535 reaction buffer Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 abstract description 22
- 108020004707 nucleic acids Proteins 0.000 abstract description 21
- 102000039446 nucleic acids Human genes 0.000 abstract description 21
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 13
- 230000008827 biological function Effects 0.000 abstract description 7
- 238000007385 chemical modification Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 20
- 210000003705 ribosome Anatomy 0.000 description 17
- 229920002477 rna polymer Polymers 0.000 description 15
- 108091023037 Aptamer Proteins 0.000 description 10
- 108020004459 Small interfering RNA Proteins 0.000 description 10
- 230000031018 biological processes and functions Effects 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 9
- 239000013566 allergen Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 108091027076 Spiegelmer Proteins 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108091005685 RIG-I-like receptors Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 108030001720 Bontoxilysin Proteins 0.000 description 2
- 102100020872 Leucyl-cystinyl aminopeptidase Human genes 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000004018 Caspase 6 Human genes 0.000 description 1
- 108090000425 Caspase 6 Proteins 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 102100032616 Caspase-2 Human genes 0.000 description 1
- 108090000552 Caspase-2 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100025597 Caspase-4 Human genes 0.000 description 1
- 101710090338 Caspase-4 Proteins 0.000 description 1
- 102100038916 Caspase-5 Human genes 0.000 description 1
- 101710090333 Caspase-5 Proteins 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 235000000509 Chenopodium ambrosioides Nutrition 0.000 description 1
- 235000005490 Chenopodium botrys Nutrition 0.000 description 1
- 244000098897 Chenopodium botrys Species 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 108091000069 Cystinyl Aminopeptidase Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000002494 Endoribonucleases Human genes 0.000 description 1
- 108010093099 Endoribonucleases Proteins 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- -1 KL 4 Proteins 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
- MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical compound CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108700022715 Viral Proteases Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Definitions
- the invention relates to novel biologically active molecules based on nucleotides, with which the expression of genes can be specifically indexed or reduced in certain cells, and an application kit for use.
- An inhibition of the expression of genes can be achieved inter alia by the introduction of siRNA (short interfering RNA) or miRNA (microRNA).
- siRNA molecules can classically interact with the mRNA of the target gene and, together with specific endoribonucleases, form an RNA-protein complex called "RISC" (RNA induced silencing complex) .
- RISC RNA induced silencing complex
- the RISC complex binds to the target mRNA, with endonucleases cleave the target mRNA to prevent gene expression, thereby inhibiting targeting.
- RNA molecules double-stranded RNA molecules
- siRNA double-stranded RNA molecules
- siRNA is designed so that these effects are suppressed.
- nucleic acids are often limited to short nucleic acid sequences; the problem with longer sequences is that the molecules are unstable and thus can not be efficiently introduced into cells via directional delivery; the known binding of short peptides to the ends of longer nucleic acids and their cell-specific cleavage often does not lead to the desired cell-specific effect, since the binding of peptides to the end of a long RNA or DNA sequence does not lead to sufficient inactivation.
- the invention is based on the object to modify long nucleic acid molecules so that by chemical modifications their biological function is reliably inactivated and cell-specific completely restored.
- nucleotide molecules are bound to nucleotide molecules in such a way that their spatial structure is so strongly changed that their biological function is no longer guaranteed or molecules normally attached to the nucleic acids no longer have access to the nucleic acids.
- the object of the present invention is achieved by single- or double-stranded nucleotide molecules with a length of more than 21 bases for introduction into cells, which are characterized in that the nucleotide molecules are at least bound to a peptide or polymer for their inactivation, which inhibits the biological activity of these molecules and which can be cleaved off by enzymes and thereby the biological effect is restored.
- at least one peptide or polymer can be attached between the ends of the nucleotides.
- at least one peptide or polymer may be attached to the backbone of the nucleotides such that both ends are bound together.
- such constructs are also provided in which at least one peptide or polymer between the ends of the nucleotides and additionally at least one peptide or polymer is bound to the backbone of the nucleotides so that both ends are bound to one another to inhibit the nucleotide molecules ,
- the present invention is based in particular in the sense of the preceding in that long nucleic acid molecules are designed so that their biological function is reliably inactivated by chemical modifications and can also be completely restored cell-specific.
- long nucleotide molecules or “long nucleic acid molecules” in the context of the present invention includes not only those having a length of more than 21 bases. In particular, those nucleotide molecules or nucleic acid molecules are also included, which have a length of more than 23 bases. Prefers are those nucleotide molecules or nucleic acid molecules that are more than 25 bases in length.
- long nucleic acid molecules are modified in the sense of the invention by chemical modifications so that their biological function is reliably inactivated and also completely cell-specifically restored, said nucleic acid molecules or nucleotide molecules having a length of more than 30, 40, 50 or more Have bases.
- nucleotide molecules are also provided for introduction into cells, which are characterized in that the nucleotide molecules for their inactivation are bound at least to a peptide or polymer which inhibits the biological activity of these molecules and which by enzymes can be cleaved and thereby the biological effect is again caused, in particular molecules are provided with a length which are in the range of 23 to 10,000 bases.
- lengths of the nucleotide molecules or nucleic acid molecules according to the invention which are in the range of 23, 25, 30, 40 or 50 to 100 bases, in particular in the range of 23 to 100 bases. These lengths are typically found in, but are not limited to, shRNA nucleotide or nucleic acid molecules, miRNAs, and antisense nucleotides.
- single or double-stranded nucleotide molecules are also provided for introduction into cells, which are characterized in that the nucleotide molecules for their inactivation is bound at least to a peptide or polymer which inhibits the biological activity of these molecules and which can be cleaved by enzymes and thereby the biological effect is again caused, in particular molecules are provided with a length which are preferably in the range of 100 to 2000 bases. These lengths are typically found in, but are not limited to, nucleotide molecules or nucleic acid molecules from the group of synthetic mRNAs, aptamers.
- nucleotide molecules are also provided for introduction into cells, which are characterized in that the nucleotide molecules for their inactivation is bound at least to a peptide or polymer which inhibits the biological activity of these molecules and which can be cleaved by enzymes and thereby the biological effect is again caused, in particular molecules are provided with a length which are preferably in the range of 2,000 to 10,000 bases. These lengths are typically found in, but not limited to, nucleotide molecules or nucleic acid molecules, such as mRNAs.
- the peptides or polymers are designed so that the Structure of the nucleotides changes and thereby their biological activity is inhibited.
- the peptides or polymers are cleaved from the nucleotides by specific enzymes, they revert to their original structure and unfold their normal biological activity.
- the cleavage by specific enzymes can be induced in particular by the fact that they show activity in specific disease or developmental states of cells (in particular cell cycle or differentiation in stem cells), specific for certain cell types or disease-relevant alteration of them (in particular degeneration or infection) or genotype-specific activity. Furthermore, a specific cleavage for the detection of certain enzymes or in the mentioned applications can take place.
- Specific enzymes may be, for example, proteases or peptidases (caspases, aminopeptidases or serine proteases, in particular caspase-1, caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, caspase-7, caspase-8, KL 4, PLAP, IRAP, uPA, FAP- ⁇ or viral PRoteases, for example HIV protease, coxsackievirus protease, Epstein Barr viras protease, hepatitis A, B, C virus protease), nucleases, glycosidases, saccharases or chitinases.
- proteases or peptidases caspases, aminopeptidases or serine proteases, in particular caspase-1, caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, caspase-7, caspase-8, KL 4, PLAP, IRAP, uPA
- binding peptides or polymers for example to micro (mi) RNA, it can be achieved that normally occurring 3d structures are modified by sequence homologies.
- binding peptides or polymers to mRNA it can be achieved, for example, that the initiation sites for the attachment of ribosomes to the mRNA are masked for translation and thus the protein encoded on the mRNA is not expressed.
- the selection of the bonds of peptides or polymers is not limited to the ends of the nucleotide molecules, but can also be done on the sugar molecules of the nucleotides, the phosphates or the organic bases.
- the nature of the single or double-stranded nucleotide molecules of the present invention is not limited to particular nucleic acid molecule or nucleotide molecule species.
- the single- or double-stranded nucleotide molecule according to the invention may be an mRNA, a DNA, a shRNA or a PNA.
- the single or double-stranded nucleotide molecule according to the invention can also be an aptamer or a spiegelmer.
- the single- or double-stranded nucleotide molecules of the invention may be immunostimulating RNAs.
- the single- or double-stranded nucleotide molecule of the present invention is provided not only in the form of one of the aforementioned single nucleotide-molecule species. Rather, in a preferred embodiment, mixtures or mixed forms of the individual species (mRNA, DNA, shRNA, PNA, immunostimulatory RNA, aptamer and / or spiegelmer) of the single- or double-stranded nucleotide molecules according to the invention are also provided.
- aptamer encompasses short single-stranded DNA or RNA oligonucleotides capable of binding a specific molecule via their three-dimensional structure
- spiegelmer encompasses L-ribonucleic acid aptamers (L-RNA aptamers for short).
- L-ribonucleic acid aptamers are ribonucleic acid (RNA) -like molecules composed of unnatural L-ribonucleotides. They are artificial Oligonucleotides and stereochemical mirror images of natural oligonucleotides.
- L-ribonucleic acid aptamers thus constitute a special form of aptamers and, like these, can bind specific molecules via their three-dimensional structure.
- L-ribonucleic acid aptamers are known under the trade name "Spiegelmer”.
- immunostimulatory RNAs are understood as meaning RNA molecules which are capable of reacting with cell-specific molecular complexes, for example RIG-I (RIG-I ("retinoic acid-inducible gene 1") is an RIG-I-like receptor dsRNA Helicase enzyme, which is a member of the family of RIG-I-like receptors (RLRs), interacts to activate a signal transduction chain and / or induce an immune response and / or apoptosis (for review, see Kawai and Akira, Ann NY Acad Sci 1 143: 1-20 (2008) and Schlee et al., Immunol Rev. 227 (1): 66-74 (2009)). These immunostimulatory RNAs may also be characterized by a 5 "triphosphate.
- An application kit for the application and administration of the biologically active nucleotide molecules, comprising at least one of them, is advantageous
- ampoule A which contains and may further contain the biologically active molecule:
- At least one further ampoule (ampule B) with a transfection system for example nanoparticles, polyethyleneimines or lipids,
- At least one further ampoule which contains further constituents for binding to the biologically active molecules or the transfection system,
- FIG. 1 Exemplary and schematic representation of an mRNA (Ia) to which biological molecules or molecular complexes, for example ribosomes (2), accumulate in the known manner and thereby trigger a biological process. Furthermore, the modification of the mRNA (lb) by, for example, a peptide (3a) is shown, whereby the attachment of the biological molecules or molecular complexes, such as ribosomes (2) and thus the triggering of a biological process is prevented. If the peptide (s) (3a) are again cleaved off from the mRNA, the biological molecules or molecular complexes (2) can re-accumulate in the known form to the mRNA (Ia) and trigger the known biological processes.
- a mRNA
- FIG. 2 Exemplary and schematic representation of an mRNA (Ia) to which biological molecules or molecular complexes, for example ribosomes (2), are deposited in the known manner, thereby triggering a biological process. Furthermore, the modification of the mRNA (lb) by, for example, a peptide (3b) is shown, whereby the spatial structure of the mRNA changes such that the attachment of the biological molecules or molecular complexes, such as ribosomes (2) and thus the triggering of a biological process is prevented. This process can be supported by the formation of double strands of RNA by random or planned homologies.
- the spatial structure of the mRNA changes again and the biological molecules or molecular complexes (2) can attach again in the known form to the mRNA (Ia) and the trigger known biological processes.
- FIG. 1 shows the exemplary mechanism by means of an mRNA (Ia).
- ribosomes (2) attach themselves to the mRNA and thereby trigger a biological process; in the case of ribosomes, translation.
- Peptide (3a) By modifying the exemplary mRNA (Ib) by a bound example Peptide (3a) prevents the attachment of, for example, the ribosomes (2).
- no translation of this mRNA (1b) can occur.
- the attachment of the exemplary ribosome (2) to the mRNA (la) is no longer prevented and there is the normal biological process, in the case of ribosomes, the translation instead.
- the binding of the peptide (3 a) can take place at the initiation site of the exemplary ribosomes or at another site of the mRNA; according to the binding site either the attachment of the ribosomes (2) or the complete reading of the exemplary mRNA is prevented.
- the normal biological function of the mRNA upon binding of the exemplary peptide can no longer occur.
- FIG. 2 shows a further possibility of the exemplary mechanism by means of an mRNA (Ia).
- mRNA mRNA
- ribosomes (2) attach themselves to the mRNA and thereby trigger a biological process; in the case of ribosomes, translation.
- exemplary mRNA (lc) a bound exemplary peptide (3b)
- the spatial structure of the exemplary mRNA is changed such that the attachment of, for example, the ribosomes (2) is prevented.
- no translation of this mRNA (1c) can occur.
- RNA induction of the production of toxic proteins in target cells:
- the RNA can be chosen so that its sequence codes for one or more sections of a toxic protein or peptide or for an entire toxic protein or peptide.
- bacterial toxins such as diphtheria, anthrax A, anthrax B, botulinum toxin or toxins of higher organisms (cones snails, snakes, lizards, insects, spiders, scorpions).
- allergens in target cells, especially in combination with transport sequences necessary for a display of allergens at the Provide cell surface, so that they are accessible to the immune system. It is particularly preferred to combine the allergen with an HLA sequence, in particular sequentially in succession, or the allergen at one point in the interior of the HLA sequence, so that allergen and HLA are presented together on the cell surface.
- HLA sequence in particular sequentially in succession, or the allergen at one point in the interior of the HLA sequence, so that allergen and HLA are presented together on the cell surface.
- Non-human allergens such as ambrosia, are particularly suitable as allergens.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102012022596.2A DE102012022596B4 (de) | 2012-11-15 | 2012-11-15 | Neue zellspezifisch wirksame Nukleotid-Moleküle und Applikationskit zu deren Anwendung |
PCT/EP2013/073887 WO2014076213A1 (de) | 2012-11-15 | 2013-11-14 | Neue zellspezifisch wirksame nukleotid-moleküle und applikationskit zu deren anwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2920305A1 true EP2920305A1 (de) | 2015-09-23 |
Family
ID=49885191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13814439.9A Withdrawn EP2920305A1 (de) | 2012-11-15 | 2013-11-14 | Neue zellspezifisch wirksame nukleotid-moleküle und applikationskit zu deren anwendung |
Country Status (7)
Country | Link |
---|---|
US (1) | US20160193362A1 (de) |
EP (1) | EP2920305A1 (de) |
JP (1) | JP2015536146A (de) |
CN (1) | CN105051191A (de) |
DE (1) | DE102012022596B4 (de) |
HK (1) | HK1211055A1 (de) |
WO (1) | WO2014076213A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016023974A1 (de) * | 2014-08-14 | 2016-02-18 | Friedrich-Schiller-Universität Jena | Peptid zur verwendung in der reduktion von nebenwirkungen in form von immunstimulatorischen reaktionen/effekten |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005021712A2 (en) * | 2003-06-25 | 2005-03-10 | Georgia Tech Research Corporation | Modified molecular beacons |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
EP0998577B1 (de) * | 1997-07-24 | 2004-10-27 | Perseptive Biosystems, Inc. | Konjugate von transportpeptiden und nukleinsäureanaloga und deren verwendung |
US8137695B2 (en) * | 2006-08-18 | 2012-03-20 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
SI1407044T2 (en) | 2000-12-01 | 2018-03-30 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Small RNA molecules that mediate RNA interference |
DE102007008596B4 (de) * | 2007-02-15 | 2010-09-02 | Friedrich-Schiller-Universität Jena | Biologisch wirksame Moleküle auf Grundlage von PNA und siRNA, Verfahren zu deren zellspezifischen Aktivierung sowie Applikationskit zur Verabreichung |
DE102009043743B4 (de) * | 2009-03-13 | 2016-10-13 | Friedrich-Schiller-Universität Jena | Zellspezifisch wirksame Moleküle auf Grundlage von siRNA sowie Applikationskits zu deren Herstellung und Verwendung |
DE102010004957A1 (de) * | 2010-01-14 | 2011-07-21 | Universitätsklinikum Jena, 07743 | Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung |
DE102010022937A1 (de) * | 2010-06-04 | 2011-12-08 | Universitätsklinikum Jena | Zellspezifisch aktivierbare biologisch wirksame Moleküle auf Grundlage von siRNA, Verfahren zu deren Aktivierung sowie Applikationskit zur Verabreichung |
CA3131967A1 (en) * | 2010-12-29 | 2012-07-05 | F. Hoffman-La Roche Ag | Small molecule conjugates for intracellular delivery of nucleic acids |
-
2012
- 2012-11-15 DE DE102012022596.2A patent/DE102012022596B4/de active Active
-
2013
- 2013-11-14 WO PCT/EP2013/073887 patent/WO2014076213A1/de active Application Filing
- 2013-11-14 JP JP2015542269A patent/JP2015536146A/ja active Pending
- 2013-11-14 EP EP13814439.9A patent/EP2920305A1/de not_active Withdrawn
- 2013-11-14 US US14/442,655 patent/US20160193362A1/en not_active Abandoned
- 2013-11-14 CN CN201380066844.XA patent/CN105051191A/zh active Pending
-
2015
- 2015-12-01 HK HK15111778.8A patent/HK1211055A1/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005021712A2 (en) * | 2003-06-25 | 2005-03-10 | Georgia Tech Research Corporation | Modified molecular beacons |
Also Published As
Publication number | Publication date |
---|---|
CN105051191A (zh) | 2015-11-11 |
DE102012022596B4 (de) | 2017-05-04 |
JP2015536146A (ja) | 2015-12-21 |
WO2014076213A1 (de) | 2014-05-22 |
US20160193362A1 (en) | 2016-07-07 |
HK1211055A1 (en) | 2016-05-13 |
DE102012022596A1 (de) | 2014-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2523692B1 (de) | Biologisch wirksame moleküle zur beeinflussung von virus-, bakterien-, parasiten-infizierten zellen und/oder tumorzellen und verfahren zu deren anwendung | |
EP1144623B1 (de) | Verfahren und medikament zur hemmung der expression eines vorgegebenen gens | |
EP2121922B1 (de) | Biologisch wirksame moleküle, insbesondere auf grundlage von pna und sirna, verfahren zu deren zellspezifischen aktivierung sowie applikationskit zur verabreichung | |
EP3199633B1 (de) | Herabregulation der genexpression mittels nukleinsäure-beladener virus-ähnlicher partikel | |
EP1951870B1 (de) | Dna-konstrukte zur spezifischen hemmung der genexpression durch rna-interferenz | |
WO2003062423A2 (de) | Verfahren zur hemmung der expression eines durch eine chromosomen-aberration entstandenen zielgens | |
DE102009043743B4 (de) | Zellspezifisch wirksame Moleküle auf Grundlage von siRNA sowie Applikationskits zu deren Herstellung und Verwendung | |
De Serres-Bérard et al. | Recent progress and challenges in the development of antisense therapies for myotonic dystrophy type 1 | |
DE60129809T2 (de) | In vitro evolution von nukleinsäuren und kodierten polypeptiden | |
DE102012022596B4 (de) | Neue zellspezifisch wirksame Nukleotid-Moleküle und Applikationskit zu deren Anwendung | |
DE102011009470A1 (de) | Biologisch wirksame Nukleotid-Moleküle zur gezielten Abtötung von Zellen, Verwendung derselben sowie Applikationskit | |
DE102010056610A1 (de) | Pharmazeutische Zusammensetzung enthaltend L-DNA | |
DE102004038535B4 (de) | Zelluläre Einschleusung von Nukleinsäurewirkstoffen | |
EP3180033B1 (de) | Peptid zur verwendung in der reduktion von nebenwirkungen in form von immunstimulatorischen reaktionen/effekten | |
DE102017103383A1 (de) | System und Verfahren zur Zelltyp-spezifischen Translation von RNA-Molekülen in Eukaryoten | |
WO2011141373A1 (de) | Verfahren zur transfektion einer eurkaryotischen zelle | |
EP2961842A2 (de) | Verfahren zur gezielten abtötung von zellen durch zur mrna-anbindung ausgerichtete nukleotid-moleküle sowie nukleotid-moleküle und applikationskit für solche verwendung | |
WO2002024931A1 (de) | Expressionssystem für funktionale nukleinsäuren | |
DE102010009445A1 (de) | Expressionsvektor zur Enzym-Expression in Zellen und Verfahren zu dessen Verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150608 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20160314 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1211055 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20180502 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1211055 Country of ref document: HK |